Making a potential $360M deal: Chimerix buys firm focusing on emerging cancer therapy
Durham-based Chimerix is buying a privately held biotech company that is focusing on emerging therapies to combat cancer.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
